ADC Therapeutics completes dose escalation in LOTIS-7 to treat r/r B-NHL

ADC Therapeutics announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA or oncastuximab tesirine-lpyl, in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma, r/r B-NHL . “The early data from Part 1 of our LOTIS-7 trial highlight the potential combinability of ZYNLONTA with bispecifics in lymphoma patients,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. “We look forward to the continued progression of this trial in 2L+ DLBCL patients.””With no or low grades of CRS and no ICANS observed among patients in Part 1 of the study, we believe LOTIS-7 demonstrates the potential for ZYNLONTA plus bispecifics to enable broader accessibility in community settings,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “Based upon the current data and coupled with the potential for additive or even synergistic efficacy with this combination, we continue to be excited about the opportunity to expand the use of ZYNLONTA in DLBCL in the future where there remains high unmet need.”